US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by TriGemX Bio

News headline image
TriGemX Bio Announces $94M Financing and Initiation of Phase 3 Trials for Elismetrep, A Potential First-in-Class Treatment for Migraine
From TriGemX Bio
Via Business Wire